Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CALCIPOTRIENE vs CALDEROL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Calcipotriene is a synthetic vitamin D3 analogue that binds to vitamin D receptors (VDR) in keratinocytes, inhibiting cell proliferation and promoting differentiation. It also modulates immune responses by reducing cytokine production.
Vitamin D analog; binds to vitamin D receptors, increasing calcium absorption in intestines and promoting bone mineralization.
Plaque psoriasis (FDA-approved),Psoriasis of the scalp (FDA-approved),Chronic plaque psoriasis (off-label),Psoriatic nails (off-label),Ichthyosis (off-label),Vitiligo (off-label)
Osteoporosis,Vitamin D deficiency,Renal osteodystrophy,Hypoparathyroidism
Apply a thin layer of 0.005% ointment, cream, or solution to affected areas once or twice daily. Maximum 100 g per week.
Oral: 0.25-0.5 mcg once daily; titration up to 1 mcg daily based on serum calcium levels. Intravenous: 0.5-2 mcg bolus; maintenance 0.5-2 mcg daily.
The terminal elimination half-life of calcipotriene is approximately 5–6 hours following topical application. Systemic clearance is rapid due to extensive hepatic metabolism, leading to minimal accumulation.
Terminal elimination half-life is approximately 20-30 hours; clinically, steady-state is achieved within 5-7 days.
Calcipotriene undergoes extensive hepatic metabolism via cytochrome P450 enzymes (mainly CYP3A4, CYP2D6, and CYP1A2) to inactive metabolites, which are excreted in feces and urine.
Hydroxylated in liver to 25-hydroxyvitamin D; further hydroxylated in kidney to active 1,25-dihydroxyvitamin D.
Calcipotriene is rapidly metabolized in the liver to inactive metabolites; less than 1% of the dose is excreted unchanged in urine. Fecal excretion accounts for approximately 70% of the administered dose, primarily as metabolites, with about 16% excreted in urine.
Primarily fecal (biliary) as unchanged drug and metabolites (approx. 80%); renal excretion accounts for less than 20%.
Calcipotriene is approximately 94% bound to plasma proteins, primarily albumin.
Approximately 99% bound to serum proteins, primarily to vitamin D-binding protein (DBP) and albumin.
Due to extensive tissue binding and lipophilicity, the apparent volume of distribution (Vd) is estimated to be >5 L/kg, indicating extensive distribution into tissues.
Vd is approximately 0.4 L/kg; reflects distribution into total body water with negligible storage in fat.
Systemic bioavailability after topical application is less than 1% when applied to normal skin (0.5–1.0%) and up to 5–6% when applied to psoriatic plaques due to increased permeability.
Oral bioavailability of calcitriol is approximately 70-90%.
No adjustment required due to minimal systemic absorption.
e GFR <30 m L/min/1.73m2: reduce dose by 50% and monitor calcium/phosphate levels; e GFR <15 m L/min/1.73m2: avoid use due to risk of hypercalcemia.
No adjustment required due to minimal systemic absorption.
Child-Pugh class B or C: reduce initial dose by 50% and titrate slowly; monitor calcium and albumin levels.
Children ≥2 years: apply 0.005% cream or ointment once daily, not exceeding 50 g per week. Safety and efficacy in children <2 years not established.
For hypocalcemia: 0.05-0.1 mcg/kg/day PO, titrated in 0.05 mcg/kg increments every 2-4 weeks; not recommended for IV use in neonates.
No specific geriatric adjustment; use caution due to increased risk of skin irritation and potential for reduced renal function.
Start at the lowest adult dose (0.25 mcg PO daily); increase cautiously due to reduced renal function; monitor serum calcium and renal function frequently.
None.
None
Hypercalcemia: Avoid exceeding recommended dose; monitor serum calcium, urine calcium, and serum phosphate in patients with renal impairment or when used with other vitamin D products.,Local skin reactions: Irritation, itching, erythema, burning; discontinue if severe.,Photosensitivity: Avoid excessive exposure to sunlight or artificial UV light.,Use on face, groin, or axillae may increase irritation.,Not recommended in patients with known disorders of calcium metabolism.
Hypercalcemia,Hypercalciuria,Renal impairment,Monitoring of serum calcium and phosphorus required
Hypercalcemia or evidence of vitamin D toxicity,Hypersensitivity to calcipotriene or any component of the formulation,Use on face, eyes, or mucous membranes
Hypercalcemia,Vitamin D toxicity,Malabsorption syndrome,Severe renal impairment
No specific food interactions. Maintain adequate calcium and vitamin D intake as per normal dietary recommendations. Avoid high-dose calcium or vitamin D supplements unless prescribed, as additive hypercalcemic risk.
Avoid high-calcium foods or supplements unless directed. Vitamin D analogs may alter calcium absorption. No specific food restriction.
Pregnancy Category C. Systemic exposure is minimal with topical use, but animal studies have shown fetal abnormalities at high doses. No adequate human studies; risk cannot be ruled out. First trimester: insufficient data; second and third trimesters: avoid unless clearly needed. Topical application at recommended doses is unlikely to cause harm, but caution advised.
FDA Pregnancy Category C. First trimester: Potential for cardiac malformations (case reports). Second/third trimester: Risk of premature closure of ductus arteriosus, oligohydramnios, and pulmonary hypertension. Avoid use after 20 weeks gestation.
Excretion into breast milk unknown. Topical calcipotriene has low systemic absorption; however, avoid application to breast area to prevent infant ingestion. M/P ratio not available. Use with caution in nursing mothers only if clearly needed.
Excreted in breast milk; M/P ratio unknown. Potential for adverse vascular effects in infants. Contraindicated in breastfeeding due to risk of ductus arteriosus constriction.
No dose adjustment required for topical use as systemic absorption is minimal. However, limit use to small areas to minimize cumulative exposure. No pharmacokinetic studies in pregnancy indicate need for dose change.
No standard dose adjustment. Use lowest effective dose for shortest duration. Contraindicated after 20 weeks gestation; avoid in first trimester if possible due to teratogenic potential.
Calcipotriene is a synthetic vitamin D3 analog used primarily for plaque psoriasis. It works by inhibiting keratinocyte proliferation and promoting differentiation. Avoid use on the face, intertriginous areas, and anogenital region due to irritation risk. Maximum weekly dose should not exceed 100 g to avoid hypercalcemia. Use with caution in patients with renal impairment or known hypercalcemia. Combination with topical corticosteroids can enhance efficacy and reduce irritation.
Calderol (calcifediol) is a vitamin D analog used for renal osteodystrophy. Monitor serum calcium and phosphate levels; do not use with severe hypercalcemia or vitamin D toxicity. Dose adjustment needed in dialysis patients.
Apply a thin layer to affected areas only, avoiding healthy skin.,Wash hands after application unless treating hands.,Do not use on the face, groin, or skin folds unless specifically directed.,Do not exceed 100 grams per week to avoid side effects.,Avoid excessive sun exposure or tanning beds during treatment.,Inform your doctor if you experience signs of high calcium: nausea, vomiting, constipation, muscle weakness.,Use exactly as prescribed; do not use occlusive dressings unless instructed.,May cause local skin irritation; report severe reactions to your doctor.
Take exactly as prescribed; do not take extra doses.,Avoid calcium supplements and antacids without consulting your doctor.,Report symptoms of hypercalcemia: nausea, vomiting, constipation, weakness, confusion.,Not for use in children.,Store at room temperature away from light and moisture.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CALCIPOTRIENE vs CALDEROL, answered by our medical review team.
CALCIPOTRIENE is a Vitamin D Analog that works by Calcipotriene is a synthetic vitamin D3 analogue that binds to vitamin D receptors (VDR) in keratinocytes, inhibiting cell proliferation and promoting differentiation. It also modulates immune responses by reducing cytokine production.. CALDEROL is a Vitamin D Analog that works by Vitamin D analog; binds to vitamin D receptors, increasing calcium absorption in intestines and promoting bone mineralization.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CALCIPOTRIENE and CALDEROL depend on the specific clinical indication. These are both Vitamin D Analog agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CALCIPOTRIENE is: Apply a thin layer of 0.005% ointment, cream, or solution to affected areas once or twice daily. Maximum 100 g per week.. The standard adult dose of CALDEROL is: Oral: 0.25-0.5 mcg once daily; titration up to 1 mcg daily based on serum calcium levels. Intravenous: 0.5-2 mcg bolus; maintenance 0.5-2 mcg daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CALCIPOTRIENE and CALDEROL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CALCIPOTRIENE is classified as Category C. Pregnancy Category C. Systemic exposure is minimal with topical use, but animal studies have shown fetal abnormalities at high doses. No adequate human studies; risk cannot be rule. CALDEROL is classified as Category C. FDA Pregnancy Category C. First trimester: Potential for cardiac malformations (case reports). Second/third trimester: Risk of premature closure of ductus arteriosus, oligohydramni. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.